Concentration of Customers and Suppliers (Tables)

12 Months Ended

Dec. 31, 2012

Concentration of Suppliers

Schedule of expenses accounted for ten percent or more of total research and development expenses

	2010
Qsymia Phase 3 studies CRO		20	%
Avanafil Phase 3 studies CRO		20	%
Clinical supplies and formulation work		12	%

Total revenues | Customer concentration

Concentration of Suppliers

Schedule of significant customers concentration

	2012
CVS		50	%
Walgreens		39	%
Express Scripts, Inc.		10	%

Gross accounts receivable | Credit concentration

Concentration of Suppliers

Schedule of significant customers concentration

	2012
CVS		51	%
Walgreens		44	%
Express Scripts, Inc.		1	%